Key result
Qiliqiangxin suppressed cardiac hypertrophy comparably to losartan in mice with pressure overload, while uniquely enhancing cardiomyocyte proliferation to ameliorate cardiac remodeling.
Why the study?
Does Qiliqiangxin improve cardiac hypertrophy, remodelling, and dysfunction in a mouse model of pressure overload compared to losartan?
Population
C57BL/6 mice undergoing transverse aorta constriction (pressure overload model)
Comparison
Qiliqiangxin (QL) 0.6 mg/kg vs Losartan 13.4 mg/kg
Design
Preclinical
Follow-up
4 weeks
Authors
Loading...
Should not change practice; hypothesis-generating for proliferation-promoting therapies in pressure-overload remodeling.
Does Qiliqiangxin improve cardiac hypertrophy, remodelling, and dysfunction in a mouse model of pressure overload compared to losartan?
In a mouse model of pressure overload, Qiliqiangxin ameliorated cardiac remodelling and function comparably to losartan, while uniquely promoting cardiomyocyte proliferation.
Zou et al. (2012) studied Cardiac hypertrophy and pressure overload. Qiliqiangxin vs. Losartan (13.4 mg/kg) was evaluated on Cardiac hypertrophy, function, and remodelling. Qiliqiangxin suppressed cardiac hypertrophy comparably to losartan in mice with pressure overload, while uniquely enhancing cardiomyocyte proliferation to ameliorate cardiac remodeling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: